ArticleNPJ breast cancer2025

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Justin M Balko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.